TitraMed helps prescribing clinicians understand where a patient's current ADHD medication dose sits relative to the efficacy peak, tolerability threshold, and licensed maximum — drawing directly on a 2026 Lancet Psychiatry network meta-analysis, the first study to map dose-response curves across all ADHD medications and age groups.
The dose thresholds shown are derived from the first dose-effect network meta-analysis of ADHD medications, published in Lancet Psychiatry in June 2026. Unlike previous analyses, it accounts for both direct and indirect evidence across all medications and age groups simultaneously, using a Bayesian framework.
The study was funded by the National Institute for Health and Care Research (NIHR) and co-authored by researchers at the University of Oxford, University of Southampton, University of Bern, and King's College London. People with lived experience of ADHD were involved in the study design and interpretation.
All thresholds represent group-level estimates from short-term RCTs (mean 7–8 weeks). They do not predict individual response. FDA licensed doses are shown as cited in the paper — UK MHRA/BNF doses may differ.